Agios Pharmaceuticals Inc. (AGIO)’s Financial Results Comparing With Theravance Biopharma Inc. (NASDAQ:TBPH)

Both Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Theravance Biopharma Inc. (NASDAQ:TBPH) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 53 21.69 N/A -5.99 0.00
Theravance Biopharma Inc. 21 20.24 N/A -4.10 0.00

In table 1 we can see Agios Pharmaceuticals Inc. and Theravance Biopharma Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Agios Pharmaceuticals Inc. and Theravance Biopharma Inc.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. 0.00% -48.2% -38.6%
Theravance Biopharma Inc. 0.00% 619.9% -47.4%

Volatility & Risk

Agios Pharmaceuticals Inc. has a beta of 2.17 and its 117.00% more volatile than Standard and Poor’s 500. From a competition point of view, Theravance Biopharma Inc. has a 1.75 beta which is 75.00% more volatile compared to Standard and Poor’s 500.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Agios Pharmaceuticals Inc. and Theravance Biopharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 0 0.00
Theravance Biopharma Inc. 0 0 2 3.00

Competitively Theravance Biopharma Inc. has a consensus price target of $55, with potential upside of 156.29%.

Insider and Institutional Ownership

Roughly 0% of Agios Pharmaceuticals Inc. shares are held by institutional investors while 88.1% of Theravance Biopharma Inc. are owned by institutional investors. 0.3% are Agios Pharmaceuticals Inc.’s share held by insiders. Competitively, Theravance Biopharma Inc. has 6.3% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 2.49% -2.96% -9.55% -6.82% -43.99% 4.34%
Theravance Biopharma Inc. 13.62% 23.08% -11.69% -17.2% -10.59% -18.52%

For the past year Agios Pharmaceuticals Inc. had bullish trend while Theravance Biopharma Inc. had bearish trend.

Summary

Agios Pharmaceuticals Inc. beats on 5 of the 8 factors Theravance Biopharma Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.